Trulicity Reviews, Results & Before/After

What the Trulicity reviews generally say

Trulicity has been on the US market since 2014. In that time it has accumulated thousands of patient reviews on pharmacy review sites, diabetes community forums, and in the clinical literature. Reviews tend to cluster around a few clear themes:

• "Better for blood sugar than for weight." The most common summary. A1c improvement is meaningful and generally exceeds expectations; weight loss is modest and often below expectations.
• "Easy to use, painless injection." The once-weekly, needle-hidden pen is almost universally praised as the simplest GLP-1 device to self-administer.
• "Rough first month, then fine." Most reviews describe an adjustment period of 2–6 weeks of GI side effects that resolve once the body adapts.
• "Plateaued after a few months." Both A1c and weight improvements tend to plateau after 3–6 months, which some reviewers find disappointing.
• "Expensive without the savings card." Cost is a recurring frustration for Medicare patients and others who cannot use the manufacturer savings card.

Trulicity A1c results

In published phase-3 clinical trials, Trulicity produced meaningful improvements in A1c at every approved dose level. These numbers describe the group mean — individual patients experience more or less reduction depending on starting A1c, background therapy, and adherence.

As a rough rule, patients starting with higher A1c levels (above 9%) tend to experience larger absolute reductions than patients starting near their target. A 1% A1c reduction is clinically meaningful and translates to approximately a 30 mg/dL drop in average blood sugar.

Trulicity weight loss results

Mean weight loss on Trulicity is modest compared to newer GLP-1 drugs, but it is real and measurable. Average weight change from the phase-3 program, rounded:

• 0.75 mg: ~1–2 kg (2–4 lb) mean weight loss over 6–12 months.
• 1.5 mg: ~2–3 kg (4–6 lb) mean weight loss over 6–12 months.
• 3.0 mg: ~3–4 kg (7–9 lb) mean weight loss over 12 months.
• 4.5 mg: ~4–5 kg (9–11 lb) mean weight loss over 12 months.

As a percentage of starting body weight, this typically corresponds to about 2–5%, with the highest doses reaching the 5% threshold the FDA uses as a minimum for "clinically meaningful" weight loss.

For context. Wegovy (semaglutide 2.4 mg) produces about 15% mean weight loss, and Zepbound (tirzepatide 15 mg) produces around 20% mean weight loss — three to five times more than Trulicity at its highest dose. See our full Trulicity weight loss guide for a complete comparison.

Trulicity before and after

"Trulicity before and after" is a common search, usually referring to weight loss photos on social media. Here is the honest reality check: the "before and after" photos most people share on Instagram and TikTok represent outliers, not averages.

• The average Trulicity patient at 12 months loses about 5–11 pounds — visible over time on the scale, but rarely dramatic in photos.
• A minority of patients lose 20+ pounds on Trulicity. These are the results most commonly posted, which skews public perception.
• Non-photographic changes — clothes fitting differently, less food noise, improved blood sugar — are reported more consistently and matter more to many patients than scale weight.

6-month and 12-month Trulicity timeline

What a typical Trulicity experience looks like, month by month:

• Weeks 1–2: Nausea is common at the starting dose (0.75 mg). Appetite starts to drop. Some patients notice fasting glucose improving within days.
• Weeks 3–4: GI side effects begin to settle. Most patients are eating smaller portions without consciously restricting. A few pounds may be lost.
• Month 2: Dose may be increased to 1.5 mg. Nausea may briefly return for 1–2 weeks, then settle again. Blood sugar continues to improve.
• Month 3: First A1c recheck. Typical patients see a 0.5–1.0 percentage-point reduction. Weight loss of 5–10 pounds is common at this point.
• Month 6: Most of the A1c and weight-loss benefit has been realized. Further titration (to 3.0 or 4.5 mg) may be considered if targets haven't been met.
• Month 12: Results plateau. Patients who continue to respond well stay the course; patients whose results are disappointing are often evaluated for a switch to a different medication.

Positive patient review themes

• "Much easier than daily insulin." Patients switching from insulin-based regimens often report relief at the simplicity of a single weekly injection.
• "A1c is the best it's been in years." Particularly common among patients previously on oral monotherapy whose A1c had drifted above target.
• "Food cravings are much quieter." Even modest appetite suppression feels dramatic to many patients who struggled with food noise before starting.
• "Lost weight without trying." Most commonly reported in the 5–15 pound range.
• "I actually remember to take it." Once-weekly dosing dramatically improves adherence compared to daily injectable or multiple-daily oral regimens.
• "Side effects were manageable." A meaningful minority of patients experience little to no GI discomfort at the starting dose.

Complaints and frustrations

• "Disappointing weight loss." By far the most common negative review, especially from patients who hoped to achieve Wegovy- or Zepbound-level results.
• "Nausea was unbearable the first month." For the minority who experience severe initial GI side effects, the adjustment period is a real hardship.
• "Sulfur burps." A strangely specific complaint that comes up frequently in reviews.
• "Worked great at first, then stopped working." Reflects either progression of underlying diabetes or real-world loss of response; usually prompts a medication change.
• "Gained weight instead of losing." Reported by a small fraction of patients, more common when Trulicity is combined with insulin or sulfonylureas.
• "Too expensive for the results." Especially among patients without insurance or the manufacturer savings card.
• "Nobody warned me about gallbladder problems." A smaller but serious complaint from patients who developed gallstones during treatment.

Who does well on Trulicity?

Based on clinical trial data and patient-reported experience, the patients who tend to get the best results on Trulicity share several characteristics:

• Type 2 diabetes with A1c in the 7.5–9.5% range. Patients with higher starting A1cs generally see larger absolute reductions.
• Not already on other strong glucose-lowering drugs. Trulicity typically performs best as an early-to-middle addition to metformin rather than as a "rescue" addition after multiple other drugs have failed.
• No significant GI disease at baseline. Patients with established GERD, gastroparesis, or significant reflux tend to tolerate Trulicity less well.
• Moderate weight loss goals. Patients who hope for 5–10% weight loss over a year are far more likely to be satisfied than patients expecting 15–20%.
• Values once-weekly dosing. Patients who prioritize convenience and simple pen use often rate Trulicity's device as the best in the GLP-1 class.
• Has commercial insurance + savings card access. The financial side of the equation dramatically changes patient experience. The same drug at $25/month reads completely differently from the same drug at $1,000/month.

Frequently asked questions